These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37417344)

  • 1. Response to "Canadians Need Improved Access to Drugs for Rare Diseases, Not More Denial".
    Sirrs S; Jiwani B; Lun E; Nakagawa B; McFarlane A
    Healthc Pap; 2023 Apr; 21(2):11-12. PubMed ID: 37417344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Guest Editor's Response to "Canadians Need Improved Access to Drugs for Rare Diseases, Not More Denial".
    Lexchin J
    Healthc Pap; 2023 Jul; 21(3):70-71. PubMed ID: 37887173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canadians Need Improved Access to Drugs for Rare Diseases, Not More Denial.
    Rawson NSB; Adams J
    Healthc Pap; 2023 Apr; 21(2):4-10. PubMed ID: 37417343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries.
    Ward LM; Chambers A; Mechichi E; Wong-Rieger D; Campbell C
    Orphanet J Rare Dis; 2022 Mar; 17(1):113. PubMed ID: 35246200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engaging the Canadian public on reimbursement decision-making for drugs for rare diseases: a national online survey.
    Polisena J; Burgess M; Mitton C; Lynd LD
    BMC Health Serv Res; 2017 May; 17(1):372. PubMed ID: 28549479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International Experiences and Made-in-Canada "Social Pharmaceutical Innovations" as Responses to Challenges Facing Drugs for Rare Diseases.
    Douglas CMW
    Healthc Pap; 2023 Jan; 21(1):66-72. PubMed ID: 36692919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific, Fair and Transparent: A Canadian Process for Funding Drugs for Rare Diseases.
    Stevenson H
    Healthc Pap; 2023 Jan; 21(1):28-33. PubMed ID: 36692913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An early examination of access to select orphan drugs treating rare diseases in health insurance exchange plans.
    Robinson SW; Brantley K; Liow C; Teagarden JR
    J Manag Care Spec Pharm; 2014 Oct; 20(10):997-1004. PubMed ID: 25278322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?
    Menon D; Clark D; Stafinski T
    Healthc Policy; 2015 Aug; 11(1):15-32. PubMed ID: 26571466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis.
    Divino V; DeKoven M; Kleinrock M; Wade RL; Kim T; Kaura S
    Orphanet J Rare Dis; 2016 May; 11(1):68. PubMed ID: 27207271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New Zealand.
    Rawson NSB
    J Popul Ther Clin Pharmacol; 2020 Jun; 27(2):e58-e67. PubMed ID: 32543163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alignment of health technology assessments and price negotiations for new drugs for rare disorders in Canada: Does it lead to improved patient access?
    Rawson NSB
    J Popul Ther Clin Pharmacol; 2020 Feb; 27(1):e48-e64. PubMed ID: 32124580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can Managed Access Agreements Mitigate Evidentiary, Economic and Ethical Issues with Access to Expensive Drugs for Rare Diseases in the Canadian Context?
    McPhail M; Bubela T
    Healthc Pap; 2023 Jan; 21(1):59-65. PubMed ID: 36692918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Historical and projected public spending on drugs for rare diseases in Canada between 2010 and 2025.
    Lech R; Chow G; Mann K; Mott P; Malmberg C; Forte L
    Orphanet J Rare Dis; 2022 Oct; 17(1):371. PubMed ID: 36209128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expensive Drugs for Rare Diseases: "Canada, We Have a Problem Here".
    Lexchin J
    Healthc Pap; 2023 Jan; 21(1):4-8. PubMed ID: 36692911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What can the Canadians and Americans learn from each other's health care systems?
    Weil TP
    Int J Health Plann Manage; 2016 Jul; 31(3):349-70. PubMed ID: 27469581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?
    Rawson NSB
    Orphanet J Rare Dis; 2022 Jun; 17(1):218. PubMed ID: 35698235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HTA criteria adopted in different models of public healthcare systems for orphan drugs: A scoping review.
    Felippini A; Biglia LV; Lima TM; Aguiar PM
    Health Policy; 2024 Jun; 144():105080. PubMed ID: 38733643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disability in two health care systems: access, quality, satisfaction, and physician contacts among working-age Canadians and Americans with disabilities.
    Gulley SP; Altman BM
    Disabil Health J; 2008 Oct; 1(4):196-208. PubMed ID: 21122730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
    Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.